Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.

J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 07 01; 390(10089):3-4.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.